Skip to content

Effect of NAVA on Weaning Duration in Difficult to Wean Patients

Department of Critical Care Medicine, Nanjing Zhong-Da Hospital, Southeast University School of Medicine, China; Department of Critical Care Medicine St. Michaels's Hospital, University of Toronto, Canada

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01280773
Enrollment
99
Registered
2011-01-21
Start date
2011-09-30
Completion date
2018-10-01
Last updated
2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weaning

Keywords

weaning, mechanical ventilation

Brief summary

It has been showed that over assist and patient ventilator asynchrony often occur in mechanical ventilated patients, especially in patients who failed weaning, which are associated with a prolonged duration of mechanical ventilation.Neurally adjusted ventilatory assist (NAVA) improves patient-ventilator synchrony, prevents excessive assist induced diaphragm inactivation. So the aim of this study was to detect that whether NAVA compared with PSV has the ability to reduce the duration of weaning in difficult to wean patients.

Detailed description

Intubated patients who were deemed ready for weaning by the clinical team but failed the first spontaneous breathing trials (SBT) or weaning were screened for eligibility. After enrollment, nasogastric tube eligible patient was replaced with a modified EAdi catheter. Then the patients were switched to a Servo-i ventilator. According to a random digits table, eligible patients were allocated randomly to ventilation with NAVA or pressure support ventilation (PSV). In PSV group, ventilator settings were determined by the physicians who in charge of the patients, and EAdi signals were not available for ventilator settings. In NAVA group, a daily NAVA level titration was performed to select the NAVA level which got approximate 50% unload, if the patients can't tolerate PSV or NAVA, PCV should be used to insure the ventilation safety. If the patients were under PCV mode, screening should be done by the researchers every 3 hours to make sure whether they will tolerate PSV or NAVA. In both group, daily measurement of diaphragmatic function was performed (only preformed in the first 10 patients of each group), followed by a 30 minutes SBT with PSV 5-7 cmH2O. Patients who were able to tolerate the SBT were extubated. Patients who completed the SBT and remained extubated \> 48 h were considered successfully extubated. Patients who failed SBT, or required noninvasive ventilation (NIV), or were re-intubated, or deceased within 48h post-extubation were considered extubation failure. Local sedation protocol including daily wakeup was performed during the research period. All continuous sedative infusions were discontinued at least 1 hour before the measurement of diaphragmatic function and SBT. Main end point was the duration of weaning, and second end point was extubation rate, diaphragmatic function and patient ventilator asynchrony.

Interventions

DEVICENAVA

Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.

Sponsors

Unity Health Toronto
CollaboratorOTHER
Ling Liu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Intubated patients who were deemed ready for weaning by the clinical team but failed the first spontaneous breathing trials (SBT) or weaning

Exclusion criteria

1. age \<18 or \>80 years, 2. tracheostomy 3. treatment abandonment 4. history of esophageal varices 5. gastro-esophageal surgery in the previous 12 months or gastro-esophageal bleeding in the previous 30 days 6. coagulation disorders (INR ratio\>1.5 and APTT\>44 s) 7. history of acute central or peripheral nervous system disorder or severe neuromuscular disease 8. history of leukemia, severe chronic liver or chronic cardiac disease 9. solid organ transplantation 10. malignant tumor.

Design outcomes

Primary

MeasureTime frameDescription
Duration of weaning48h after extubationDuration of weaning was defined as time from study enrollment to extubation.

Secondary

MeasureTime frameDescription
Extubation rate48h after extubation or 30 day after enrollmentExtubation rate was defined as the percentage of patients with successful weaning
diaphragmatic functionAt 8 am daily before extubatiuonDiaphragmatic function was measured by neuro-ventilatory efficiency (NVE), a ratio of tidal volume to diaphragm electrical activity (Vt/EAdi), and neuro-mechanical efficiency (NME), a ratio of airway pressure to EAdi(Paw/EAdi) during airway occlusion. diaphragmatic function
Patient ventilator asynchronyAt 8 am daily until extubationTime delay between neuro inspiration and ventilator delivery. Time delay between neuro expiration and ventilator cycle-off.

Other

MeasureTime frameDescription
MortalityICU or hospital discharge or 28dayICU, 28 day and hospital mortality

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026